1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

US FDA's New Website May Facilitate Broader Outside Use Of Data

 
• By Derrick Gingery

Redesigned FDA.gov is expected to allow application programming interfaces, which could allow other software to talk to the site and potentially use its data.

New and old view of FDA website
FDA redesigned its website to appear better on mobile devices, in part because more than half of site visits originate from them.

The US Food and Drug Administration's redesigned website eventually may allow easier use of its data by outside groups, as well as improve the user experience.

The new FDA.gov, which launched on 26 April, has a more modern user interface that will improve accessibility no matter the device used to view it.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Pink Sheet Podcast: US FDA’s Big Vaccine Policy Week

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss the new clinical trial requirements that the FDA announced for COVID-19 vaccines, the updated label for Novavax’s newly approved COVID-19 vaccine, and other vaccine-related events that were part of a busy week for policy in the sector.

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

More from Agency Leadership